| IVZ |
Report |
Adjusted diluted EPS |
IN-LINE |
pred ~$0.670 vs. cons $0.664 |
MEDIUM |
| IVZ |
Report |
Operating net revenue |
IN-LINE |
pred ~$1.340B vs. cons $1.333B |
MEDIUM |
| IVZ |
Report |
Long-term net flows |
IN-LINE |
pred ~$45.0B vs. cons $44.97B |
HIGH |
| IVZ |
Guide |
FY26 operating expenses |
UNCHANGED |
guide ~$3.275B vs. cons UNVERIFIED |
LOW |
| IVZ |
Guide |
Q3/Q4 Canadian operating-income impact |
UNCHANGED |
guide ~$5M-$10M quarterly headwind vs. cons UNVERIFIED |
LOW |
| IVZ |
Guide |
Margin / yield commentary |
UNCHANGED |
maintain high-30s margin path; QQQ mix pressure on yield vs. cons UNVERIFIED |
LOW |
| IVZ |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.0% |
— |
LOW |
| IVZ |
Return |
5-day cumulative residual |
-3.5% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — in-line package does not validate the pre-print rerating |
LOW |